Cagrilintide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: amylin signaling and appetite regulation

Metabolic Research peptide LyophilizedInjection verified

Also known as: Cagrilintide

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 mg RUO vial, 10 mg RUO vial, 20 mg RUO vial, Clinical injection formulation

Calculator

Preset available

Storage

Investigational compound - no FDA label. Use source COA / vendor storage guidance and verify independently before recording.

Solubility

Clinical formulation is product-specific and mildly acidic; no universal reconstitution instruction exists for gray-market lyophilized material

Catalog Description

Cagrilintide is an acylated long-acting amylin analog developed for once-weekly subcutaneous administration. A Phase 2 dose-finding trial studied 0.3-4.5 mg weekly, and 2025 Phase 3 trials evaluated 2.4 mg cagrilintide alone and co-administered with 2.4 mg semaglutide. These results support investigational clinical evidence but do not make gray-market lyophilized vials equivalent to the investigational trial formulation. Cagrilintide remains unapproved as of July 2026.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Approximately 180 hours (about 7-8 days) based on published Phase 1/1b pharmacokinetic data, consistent with once-weekly dosing; steady state is reached after about 5 weeks of repeated dosing.

Onset

Pharmacologic exposure is sustained weekly; efficacy outcomes were assessed over months

Administration Routes (Research)

Subcutaneous (SC)

Reported Research Effects

Amylin and calcitonin-receptor agonism
Dose-dependent body-weight reduction in Phase 2
Phase 3 evidence for cagrilintide-semaglutide coadministration
Gastrointestinal tolerability limits

Reported Research Side Effects

Nausea vomiting constipation and other gastrointestinal events
Long half-life can prolong intolerance
Gray-market identity sterility concentration and pH are unverified

Data source: Primary Phase 2 and Phase 3 trials, ClinicalTrials.gov, and current RUO market checks

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established

Subcutaneous (SC) Human study only

Phase 2 monotherapy arms targeted 0.3, 0.6, 1.2, 2.4, or 4.5 mg once weekly after an escalation period of up to 6 weeks; the publication does not support substituting a single universal ladder across all arms

Frequency / timing: Weekly
Duration / setting: 26-week investigational trial
Technique: SC
Evidence: Human study protocol

Context: Lancet Phase 2 trial PMID 34798060

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.

Source 1 Source 2 Source 3 Source 4

Subcutaneous (SC) Human study only

CagriSema research ladder: weeks 1-4 0.25 mg cagrilintide plus 0.25 mg semaglutide; weeks 5-8 0.5 plus 0.5 mg; weeks 9-12 1.0 plus 1.0 mg; weeks 13-16 1.7 plus 1.7 mg; week 17 onward 2.4 plus 2.4 mg

Frequency / timing: Weekly
Duration / setting: 16-week investigational escalation then maintenance
Technique: SC
Evidence: Human study protocol

Context: REDEFINE program and the developer fixed-dose patent

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.

Source 1 Source 2 Source 3 Source 4

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Interactions

Commonly Stacked With (Research)

Semaglutide (tested clinical coadministration only)

Flagged Avoid / Caution Combinations (Research)

Insulin or other glucose-lowering therapy without protocol-specific monitoring

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

Cagrilintide remains investigational in the United States. The exact Phase 2 monotherapy escalation differed by assigned target and was only described publicly as lasting up to six weeks; a community 0.25-to-2.4 mg ladder must not be mislabeled as that Phase 2 monotherapy protocol. The explicit 0.25-to-2.4 mg matched ladder belongs to the CagriSema development program.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Once-weekly cagrilintide Phase 2 dose-finding trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/34798060/

Cagrilintide plus semaglutide REDEFINE 1 Phase 3 trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/40544433/

REDEFINE 1 study record — ClinicalTrials.gov
https://clinicaltrials.gov/study/NCT05567796

Fixed-dose cagrilintide and semaglutide escalation disclosure — Google Patents
https://patents.google.com/patent/BR122025017079A2/en

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Where to Source Cagrilintide

The following are third-party vendor links for this compound, provided for reference only. Some may be affiliate links, and prices/coupons are entered manually and may not always reflect the vendor's current listing. No affiliation, endorsement, or product claim is implied. Verify price, coupon validity, and product specifications directly on the vendor's site before purchase.

COA verified

Cagrilintide

G1P-4 CG 5mg G1P-4 CG 5mg — Full 10-Vial Kit

Hacker Peptides

In stock

$40.00 $29.99

-25.03%

Shop ↗

Third-party links — not affiliated with this site. Not a recommendation for human use. Research compounds are for laboratory and educational use only.

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.